CD274 and cancer: Studies across a variety of solid tumors have documented a statistically significant association between higher pretreatment body mass index (BMI) and improved survival outcomes in cancer patients receiving antibodies blocking the programmed cell death protein-1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway [1].